Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|February 27, 2023

BP Elements

  • BioPharm International's BP Elements, March 2023
  • Volume 2
  • Issue 3

Bio-Rad’s New StarBright Blue and Yellow Dyes Enhance Multiplex Flow Cytometry

Bio-Rad’s newly launched StarBright Blue and StarBright Yellow dyes are intended for use in various flow cytometry applications.

Bio-Rad Laboratories introduced its new StarBright Blue and StarBright Yellow dyes in February 2023. The dyes are designed to promote flexibility in conventional and full spectrum flow cytometry applications. Dyes in the Starbright series are conjugated to flow validated antibodies, supporting flow cytometry panel design in immunology design.

The two new variations in the Starbright series are intended to expand research capabilities across blue (488 nanometers) and yellow (561 nanometers) lasers. According to a Feb. 13, 2023 press release, the new dyes offer exceptional brightness in conjunction with narrow excitation and emission profiles, allowing for precise resolution.

StarBright dyes are compatible with most experimental protocols and flow cytometers without the need for special buffers. Additionally, minimal lot-to-lot variation helps to ensure reproducible and consistent staining, and the dyes are resistant to photobleaching with no loss of signal in fixation, according to the release.

"The continued development of the Bio-Rad StarBright Dye portfolio, now totaling 28 dyes and spanning multiple lasers, gives researchers greater choice and flexibility across multiplex flow cytometry applications, offering superior alternatives to existing dyes," said Mike Blundell, product manager, Flow Cytometry, Life Science Group, Bio-Rad, in the release. "With the launch of the StarBright Blue and StarBright Yellow Dyes, Bio-Rad now has the most comprehensive series of new dyes specifically designed for flow cytometry."

Source: Bio-Rad


Related to this article

The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.